Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Glutamate exposure reduces MAP-2 immunostaining and induces changes in synaptic markers and cell adhesion molecule NCAM in the absence of neuronal death. by María Fernanda Podestá (639243)

“…<p>Hippocampal neurons in culture (DIV 12–13) were briefly exposed to 5 µM glutamate and evaluated 24 h later. (A) Microphotographs of hippocampal neurons in culture immunostained for MAP-2 or visualized by phase contrast microscopy. …”

Pharmacologically induced torpor by 5′-AMP does not decrease platelet count despite decreased body temperature. by Edwin L. de Vrij (550179)

“…<p>A) Pharmacologically induced torpor by 5′-AMP in mice does not decrease platelet count during torpor and shows an increase upon arousal. …”

Western blot analysis of MPK-1 levels in WT and <i>let-60</i> mutants. by Maximilian Kramer-Drauberg (8981141)

Structure of P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Fig 5 - by Jacob C. Jentzer (4746999)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Mean and standard deviation of vascular density. by Beatriz Cordon (9745619)

Cellular immune responses against SARS-CoV-2 in subgroup participants (PLWH). by Kathryn S. Hensley (14019217)

Mean-difference plots by country: Countries with decreased variance and no change in mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with decreased variance and increased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with increased variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with no change in variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

NS attenuates ox-LDL-induced foam cell formation. by Yihua Wang (491766)

Difference in mean Opportunity scores by gender among people with TB. by Kevin Guzman (16474985)